Tevapharm India Profile
Key Indicators
- Authorised Capital ₹ 700.00 Cr
as on 16-06-2024
- Paid Up Capital ₹ 220.19 Cr
as on 16-06-2024
- Company Age 24 Year, 19 Days
- Last Filing with ROC 31 Mar 2023
- Revenue 36.67%
(FY 2023)
- Profit 29.00%
(FY 2023)
- Ebitda 33.67%
(FY 2023)
- Net Worth -6.56%
(FY 2023)
- Total Assets 2.48%
(FY 2023)
About Tevapharm India
The Corporate was formerly known as Ratiopharm India Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 700.00 Cr and a paid-up capital of Rs 220.19 Cr, as per Ministry of Corporate Affairs (MCA) records.
Nishank Bhargava and Vinod Shetty serve as directors at the Company.
- CIN/LLPIN
U33111MH2000FTC326700
- Company No.
326700
- Company Classification
Private Limited Foreign Company Incorporated In India
- Incorporation Date
01 Dec 2000
- Date of AGM
22 Aug 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Tevapharm India?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Nishank Bhargava  | Director | 24-Feb-2022 | Current |
| Vinod Shetty | Director | 24-Aug-2021 | Current |
Financial Performance and Corporate Structure Insights of Tevapharm India.
Tevapharm India Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 36.67% increase. The company also saw a substantial improvement in profitability, with a 29% increase in profit. The company's net worth dipped by a decrease of 6.56%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Tevapharm India?
In 2023, Tevapharm India had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Teva Pharmaceutical And Chemical Industries India Private LimitedActive 21 years 7 monthsNishank Bhargava and Vinod Shetty are mutual person
Actavis Pharma Development Centre Private LimitedActive 18 years 4 monthsNishank Bhargava and Vinod Shetty are mutual person
Teva Global Business Services Private LimitedActive 20 years 4 monthsNishank Bhargava and Vinod Shetty are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Tevapharm India?
Tevapharm India has a workforce of 973 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Tevapharm India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Tevapharm India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
